These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 11036840

  • 1. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.
    J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
    [Abstract] [Full Text] [Related]

  • 2. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA.
    N Engl J Med; 1997 Aug 07; 337(6):382-7. PubMed ID: 9241127
    [Abstract] [Full Text] [Related]

  • 3. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.
    J Rheumatol; 2003 Dec 07; 30(12):2673-9. PubMed ID: 14719212
    [Abstract] [Full Text] [Related]

  • 4. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

  • 5. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A.
    J Rheumatol; 1994 Oct 12; 21(10):1922-6. PubMed ID: 7837160
    [Abstract] [Full Text] [Related]

  • 6. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH.
    J Rheumatol; 1999 Jul 12; 26(7):1545-9. PubMed ID: 10405943
    [Abstract] [Full Text] [Related]

  • 7. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.
    J Rheumatol; 2008 Jan 12; 35(1):142-6. PubMed ID: 18050368
    [Abstract] [Full Text] [Related]

  • 8. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T, Kollerup G, Thamsborg G, Genant HK, Sørensen OH.
    J Rheumatol; 1996 Sep 12; 23(9):1560-4. PubMed ID: 8877926
    [Abstract] [Full Text] [Related]

  • 9. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T, Maekawa S, Morinobu S, Morinobu A, Koshiba M, Yamauchi M, Sugimoto T, Kumagai S.
    Ryumachi; 2002 Aug 12; 42(4):666-75. PubMed ID: 12355861
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM, Hillner BE.
    J Rheumatol; 2003 Jan 12; 30(1):132-8. PubMed ID: 12508402
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B.
    J Clin Endocrinol Metab; 1998 Apr 12; 83(4):1128-33. PubMed ID: 9543129
    [Abstract] [Full Text] [Related]

  • 13. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH.
    N Engl J Med; 1990 May 03; 322(18):1265-71. PubMed ID: 2109197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug 03; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy.
    Skingle SJ, Moore DJ, Crisp AJ.
    Int J Clin Pract; 1997 Sep 03; 51(6):364-7. PubMed ID: 9489064
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA.
    Arthritis Rheum; 1999 Nov 03; 42(11):2309-18. PubMed ID: 10555025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.